SEATTLE

,

Dec. 2, 2021

/PRNewswire/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Hematology & Oncology Summit at

3:40 p.m. ET

. The conference will be held in a virtual meeting format.

Presentation details:

Event: JMP Securities Hematology & Oncology Summit

Date:

Monday, December 6

, 2021

Time:

3:40 p.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at

www.ctibiopharma.com

.

About CTI BioPharma Corp.


We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development. We are headquartered in

Seattle, Washington

.

CTI BioPharma Investor Contacts:


Argot Partners

+212-600-1902


[email protected]

View original content to download multimedia:

https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-hematology–oncology-summit-on-monday-december-6-301436710.html

SOURCE CTI BioPharma Corp.